Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cemacabtagene ansegedleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cemacabtagene ansegedleucel overview
Cemacabtagene ansegedleucel (Cema-Cel, ALLO-501A) is under development for the treatment of diffuse large B-cell Lymphoma, marginal zone B-cell Lymphoma, primary mediastinal B-cell Lymphoma, r/r chronic lymphocytic leukemia (CLL) and follicular lymphoma. The drug candidate is an anti-CD19 Allogeneic CAR T (AlloCAR T) therapy in which a T cell receptor gene is knocked out to avoid GvHD and the CD52 gene is knocked out to render the drug resistant to anti-CD52 antibody treatment which can be used to suppress the host immune system. It is administered by intravenous route of administration.
Allogene Therapeutics overview
Allogene Therapeutics is a clinical-stage biotechnology company. It primarily focuses on the development of investigational allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune diseases. The company’s pipeline product includes ALLO-501, ALL0-501A, ALL0-316, ALL0-819, ALL0-605 and ALL0-715. Its ALL0-501 and ALL0-501A an off-the-shelf allogeneic CAR T therapy candidates for the treatment of hematological malignancies, CD70 and DLL3 for solid tumors and ALLO-647, an anti-CD52 monoclonal antibody used as lymphodepleting agent. Allogene Therapeutics‘ products are targeted towards patients suffering from blood cancers, solid tumors, and autoimmune diseases. The company operates primarily in the biotechnology and healthcare sectors, focusing on the development and manufacturing of cell therapy products. Allogene Therapeutics is headquartered in South San Francisco, California, the US.
For a complete picture of Cemacabtagene ansegedleucel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
